[HTML][HTML] Drug resistance and combating drug resistance in cancer
Cancer is the second leading cause of death in the US. Current major treatments for cancer
management include surgery, cytotoxic chemotherapy, targeted therapy, radiation therapy …
management include surgery, cytotoxic chemotherapy, targeted therapy, radiation therapy …
Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
ZF Lim, PC Ma - Journal of hematology & oncology, 2019 - Springer
The biggest hurdle to targeted cancer therapy is the inevitable emergence of drug
resistance. Tumor cells employ different mechanisms to resist the targeting agent. Most …
resistance. Tumor cells employ different mechanisms to resist the targeting agent. Most …
[HTML][HTML] ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours …
The development of guidelines recommendations is one of the core activities of the
European Society for Medical Oncology (ESMO) and European Society of Gynaecologial …
European Society for Medical Oncology (ESMO) and European Society of Gynaecologial …
Clonal expansion in non-cancer tissues
N Kakiuchi, S Ogawa - Nature Reviews Cancer, 2021 - nature.com
Cancer is a clonal disorder derived from a single ancestor cell and its progenies that are
positively selected by acquisition of 'driver mutations'. However, the evolution of positively …
positively selected by acquisition of 'driver mutations'. However, the evolution of positively …
Clonal heterogeneity and tumor evolution: past, present, and the future
N McGranahan, C Swanton - Cell, 2017 - cell.com
Intratumor heterogeneity, which fosters tumor evolution, is a key challenge in cancer
medicine. Here, we review data and technologies that have revealed intra-tumor …
medicine. Here, we review data and technologies that have revealed intra-tumor …
Uncovering novel mutational signatures by de novo extraction with SigProfilerExtractor
Mutational signature analysis is commonly performed in cancer genomic studies. Here, we
present SigProfilerExtractor, an automated tool for de novo extraction of mutational …
present SigProfilerExtractor, an automated tool for de novo extraction of mutational …
High grade serous ovarian carcinomas originate in the fallopian tube
SI Labidi-Galy, E Papp, D Hallberg, N Niknafs… - Nature …, 2017 - nature.com
High-grade serous ovarian carcinoma (HGSOC) is the most frequent type of ovarian cancer
and has a poor outcome. It has been proposed that fallopian tube cancers may be …
and has a poor outcome. It has been proposed that fallopian tube cancers may be …
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
LE Kandalaft, D Dangaj Laniti, G Coukos - Nature Reviews Cancer, 2022 - nature.com
Abstract Treatment of high-grade serous ovarian cancer (HGSOC) remains challenging.
Although HGSOC can potentially be responsive to immunotherapy owing to endogenous …
Although HGSOC can potentially be responsive to immunotherapy owing to endogenous …
Ovarian cancer
UA Matulonis, AK Sood, L Fallowfield… - Nature reviews Disease …, 2016 - nature.com
Ovarian cancer is not a single disease and can be subdivided into at least five different
histological subtypes that have different identifiable risk factors, cells of origin, molecular …
histological subtypes that have different identifiable risk factors, cells of origin, molecular …
Cancer stemness, intratumoral heterogeneity, and immune response across cancers
Regulatory programs that control the function of stem cells are active in cancer and confer
properties that promote progression and therapy resistance. However, the impact of a stem …
properties that promote progression and therapy resistance. However, the impact of a stem …